Summary
The aim of this study was to determine whether there were differences in the oxidative deamination of dopamine in patients with Parkinson’s disease who demonstrated a long-duration response (LDR) to treatment with dopa and carbidopa and in patients who demonstrated only a short-duration response (SDR) to the drugs. The patients who demonstrated LDR had received dopa and carbidopa for a shorter time (3.4 y) than had the SDR patients (9.5 y). The concentrations of dopamine and 3-methoxytyramine and their deaminated metabolites 3,4-dihydroxyphenylacetic acid and homovanillic acid were measured in 24-h urine samples collected from patients in both groups. The ratios of homovanillic acid to 3-methoxytyramine and dopamine were greater in SDR than in LDR patients suggesting increased oxidative deamination of dopamine in this group. Increased oxidative deamination could be caused by an increase in MAO activity as Parkinson’s disease progresses or by the treatment with L-dopa.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with “Madopar” and L-deprenil in Parkinson’s disease. Lancet i: 439–443.
Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) Potentiation of anti-akinetic effect after L-dopa treatment by an inhibitor of MAO-B, deprenil. J Neural Transm 36: 303–323.
Dairman W, Udenfriend S (1971) Decrease in adrenal tyrosine hydroxylase and increase in norepinephrine synthesis in rats given L-dopa. Science 171: 1022–1024.
Hoeldtke R, Rogawski M, Wurtman RJ (1974) Effect of selective destruction of central and peripheral catecholamine-containing neurones with 6-hydroxydopamine on cate-cholamine excretion in the rat. Br J Pharmacol 50: 265–270.
Jellinger K, Riederer P (1984) Dementia in Parkinson’s disease and (pre)senile dementia of Alzheimer type. Morphological aspects and changes in the intracerebral MAO activity. Adv Neurol 40: 199–210.
Knoll J (1986) Critical role of MAO inhibition in Parkinson’s disease. Adv Neurol 45: 107–110.
Lewitt PA, Oxenkrug GF, McIntyre IM, McCauley RM (1985) Peripheral carbidopa effects monoamine oxidase. Neurology 35: 1258–1259.
Molinoff PB, Brimijoin S, Axelrod J (1972) Induction of dopamine-β-hydroxylase and tyrosine hydroxylase in rat hearts and sympathetic ganglia. J Pharmacol Exp Ther 182: 116–129.
Muenter MD, Tyce GM (1971) L-Dopa therapy of Parkinson’s disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 46: 231–239.
Muskiet FAJ, Fremouw-Ottevangers DC, van der Meulen J, Wolthers BG, de Vries JA (1978) Determination of some L-3,4-dihydroxyphenylalanine and dopamine metabolites in urine by means of mass fragmentography. Clin Chem 24: 122–127.
Naoi M, Nagatsu T (1987) Inhibition of monoamine oxidase by 3,4-dihydroxyphenyl-L-alanine and its analogues. Life Sci 40: 321–328.
Sharpless NS, Tyce GM, Muenter MD, Dinapoli RP (1974) Dopa, 3-O-methyldopa, and metabolites in urine during oral L-3-O-methyldopa therapy. Clin Pharmacol Ther 16: 770–781.
Sharpless NS, Tyce GM, Owen CA Jr (1973) Effect of chronic administration of L-dopa on catechol-O-methyltransferase in rat tissues. Life Sci 12: 97–106.
Spina MB, Cohen G (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson’s disease. Proc Natl Acad Sci 86: 1398–1400.
Strolin-Benedetti MS, Dostert P (1989) Monoamine oxidase, brain ageing and degenerative diseases. Biochem Pharmacol 38: 555–561.
Tate SS, Sweet R, McDowell FH, Meister A (1971) Decrease of the 3,4-dihydroxyphen-ylalanine (DOPA) decarboxylase activities in human erythrocytes and mouse tissues after administration of DOPA. Proc Natl Acad Sci 68: 2121–2123.
Tryding N, Tufvesson G, Nilsson S (1971) Serum-monoamine-oxidase levels during levodopa therapy. Lancet i: 859.
Tyce GM, Rorie DK (1982) Conjugated dopamine in superfusates of slices of rat striatum. J Neurochem 39: 1333–1339.
Weiss JL, Cohn CK, Chase TN (1971) Reduction of catechol-O-methyltransferase activity by chronic L-dopa therapy. Nature 234: 218–219.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag
About this chapter
Cite this chapter
Tyce, G.M., Dousa, M.K., Muenter, M.D. (1990). MAO and L-DOPA treatment of Parkinson’s disease. In: Youdim, M.B.H., Tipton, K.F. (eds) Neurotransmitter Actions and Interactions. Journal of Neural Transmission, vol 29. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9050-0_22
Download citation
DOI: https://doi.org/10.1007/978-3-7091-9050-0_22
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82142-8
Online ISBN: 978-3-7091-9050-0
eBook Packages: Springer Book Archive